

## Regenerative Therapy of Deep Peri-implant Infrabony Defects After CO<sub>2</sub> Laser Implant Surface Decontamination



Georgios E. Romanos, DDS, Dr Med Dent, PhD\*  
 Georg H. Nentwig, DMD, Dr Med Dent, PhD\*\*

*The treatment of a peri-implant infrabony defect is difficult because of contamination of the implant surface and adjacent tissues. This case series addresses the ability of a carbon dioxide (CO<sub>2</sub>) laser to decontaminate failing implants in 15 patients. Clinical and radiologic data are presented with regard to using the laser in combination with bone grafting and a barrier. Augmentation with autogenous bone grafting material (n = 10) or a xenogenic bone grafting material (BioOss) (n = 9) was used, and bone grafts were covered with a collagen membrane. Clinical and radiologic parameters were evaluated postoperatively. After an observation period of 27 months (± 17.83), almost complete bone fill in the peri-implant defect was accomplished. These preliminary clinical and radiologic findings suggest that decontamination of the implant surfaces with the CO<sub>2</sub> laser in combination with augmentative techniques can be an effective treatment method for peri-implantitis. (Int J Periodontics Restorative Dent 2008;28:245–255.)*

\*Professor of Clinical Dentistry and Director of the Unit of Laser Dentistry, Divisions of Periodontology and General Dentistry, Eastman Department of Dentistry, University of Rochester, New York.

\*\*Director, Department of Oral Surgery and Implantology, Johann Wolfgang Goethe University of Frankfurt, Germany.

Correspondence to: Dr George E. Romanos, Eastman Department of Dentistry, University of Rochester, 625 Elmwood Avenue, Rochester, 14620 NY; e-mail: Georgios\_Romanos@urmc.rochester.edu.

Today, a large number of endosseous implants are being placed, usually with a high survival rate.<sup>1</sup> However, over a 5-year period, 0% to 14.4% of dental implants demonstrate peri-implant inflammatory reactions associated with crestal bone loss.<sup>2</sup> In general, there is a dearth of data regarding how to manage peri-implantitis.<sup>3</sup>

To cease bone loss caused by peri-implantitis and attain regeneration around implants, decontamination of the implant surface is necessary.<sup>4–6</sup> Ideally, bone-to-implant contacts should be increased, and implants should become reosseointegrated. At present, there is no evidence regarding the utility of anti-infective treatment to prolong the longevity of an implant. There is also insufficient evidence to support any specific treatment strategy for peri-implantitis.<sup>7,8</sup>

Numerous treatments have been recommended, and various methods of implant decontamination have been reported.<sup>9</sup> Guided bone regeneration has been used for the treatment of peri-implant bony defects<sup>5,10,11</sup>; however, this procedure has limited predictability.<sup>12</sup> In general, peri-implant bony defects are characterized by poor

bone regenerative capacity adjacent to contaminated implant surfaces.<sup>13</sup> Currently, there are no clinical studies or case series documenting successful regenerative procedures in peri-implant bony lesions. Some case series have demonstrated limited bone fill after guided bone regeneration procedures.<sup>4</sup> To enhance these results, investigators suggested that it would be necessary to decontaminate failing implant surfaces.<sup>4,14</sup> Subgingival irrigation with local disinfectants was used,<sup>14-16</sup> and local antibiotic therapy with tetracycline fibers was employed, but neither treatment provided a conclusive therapeutic effect.<sup>17</sup> Systemic antimicrobial administration of antibiotics was used in the treatment of peri-implantitis; however, the results were limited because of resistant strains of bacteria and ineffective drug dosages.<sup>18,19</sup> In contrast, encouraging results were reported using a carbon dioxide (CO<sub>2</sub>) laser in dogs as a decontamination device to improve reosseointegration.<sup>20</sup> This animal study suggested that the laser may be an effective therapeutic modality in the treatment of peri-implantitis. Thus, in humans, it was decided to evaluate clinically and radiologically the prognosis of failing implants with deep infrabony defects that were decontaminated with the CO<sub>2</sub> laser, augmented with grafting material, and covered with a membrane.

### Method and materials

Fifteen patients (five men, ten women; mean age: 57.21 ± 12.14 years) manifesting 19 deep peri-implant infrabony defects were treated in the Department

of Oral Surgery and Implantology of the University of Frankfurt, Frankfurt, Germany. The implants were not mobile and showed bone loss over two thirds of their length. Four implants that were originally submerged, uncovered, and restored were included in the study. These implants developed peri-implantitis after the final prosthetic restoration was placed. The other 15 implants were submerged, and developed peri-implantitis before being uncovered and restored. These implants were considered early failures. Clinical and radiologic parameters were evaluated before surgical intervention to determine the need for defect augmentation. The Plaque Index and Sulcus Bleeding Index were recorded before surgery. The mean probing depth was 6.0 ± 2.03 mm. The width of the keratinized mucosa was 2.30 ± 1.45 mm before surgery. Bone loss was recorded as horizontal or vertical loss.

### *Surgical technique*

A full-thickness mucoperiosteal flap was elevated after local anesthesia to facilitate implant exposure and gain access to peri-implant bony defects. Granulomatous tissue was removed using titanium curettes. Intraosseous defects had a mean probing depth of 6.95 ± 1.84 mm. A CO<sub>2</sub> laser (SC 20, Weil Dental or Smart US-20D, DEKA) was used to irradiate the exposed implant surfaces for a total period of 1 minute. The power setting was 2.84 ± 0.83 watts, which promoted blood coagulation in the bony defect. The coagulum formed as a result of the laser irradiation and remained as a clot


**Table 1** Peri-implant defects according to treatment

Patient	Age (y)	Site (FDI)	Implant	Defect (mm)	Defect morphology	Graft material	Power setting (W)
1	5	34	Ankylos	7.0	1-wall	BioOss	2
2	24	35	Ankylos	8.0	1-wall	Autogenous bone	3
3	50	36,37	ITI	6.6	1-wall	Autogenous bone	2
4	73	34	Ankylos	10.0	3-wall	BioOss	4
5	53	36,37	IMZ	8.8	2-wall	BioOss	4
6	77	46	Ankylos	7.0	1-wall	Autogenous bone	3
7	57	34	Ankylos	7.0	1-wall	Autogenous bone	2
8	45	23	Ankylos	8.0	2-wall	BioOss	2
9	63	11	Ankylos	12.0	2-wall	BioOss	2
10	58	36,37	Ankylos	9.4	2-wall	BioOss	3
11	72	45	ITI	4.0	3-wall	Autogenous bone	2
12	49	15	Ankylos	6.0	2-wall	Autogenous bone	2
13	58	34	Ankylos	11.0	2-wall	BioOss	2
14	58	46,47	Ankylos	8.8	1-wall	Autogenous bone	3
15	65	32	Ankylos	12.0	3-wall	Autogenous bone	4

in the defect. Ten bony lesions were augmented with autogenous bone. Bone was taken from the chin, ramus, or tuberosities. The harvested bone was milled with a bone mill. Nine defects were augmented with a cancellous bone grafting material (BioOss Osteohealth) (Table 1). The augmented sites were covered with collagen membranes (BioGide, Osteohealth), and the membranes were fixed in place with titanium pins (Frios, Friadent). Mucoperiosteal flaps were closed with 4-0 silk sutures (Resorba). No systemic antibiotic therapy was used preoperatively or postoperatively.

Four implants were loaded with the final restorations immediately after the augmentation procedure, while the remaining 12 implants were submerged after bone augmentation. Sutures were removed 1 week after surgery. Reexamination of the implants was performed at 1 month and 3, 6, and 9 months and then once a year for the entire observation period. Clinical and radiologic parameters were evaluated at each recall visit over the entire observation period using conventional radiographs (panoramic or periapical) (Figs 1 to 3).





**Fig 1a** (left) Radiologic bone loss extending to the middle third of the implant.

**Fig 1b** (right) Peri-implant bony destruction.



**Fig 1c** (left) Irradiation of the implant surface with a CO<sub>2</sub> laser (noncontact).

**Fig 1d** (right) Radiograph 35 months postoperatively showing no bone loss.



**Fig 2a** Infrabony defect (12 mm).



**Fig 2b** CO<sub>2</sub> laser irradiation of the infrabony defect (noncontact).




**Fig 2c** Complete bone fill after 1 year of implant loading (1.5 years after surgery).

## Results

After an observation period of  $27.10 \pm 17.83$  months, all implants were examined clinically and radiologically. No peri-implant inflammatory reaction (eg, bleeding or suppuration) was noted during the observation period (Table 2). Clinical parameters such as Sulcus Bleeding Index and probing depth

presented a significant reduction during the examination period ( $P < .01$ ) (Table 2). No significant difference was found in terms of Plaque Index or width of keratinized mucosa during the total observation period (Table 2). Complete bone fill was radiologically observed in all defects (Table 3) after the use of the xenogenic bone grafting material (BioOss). In all sites treated



**Fig 3a** (left) Radiolucency during the implant healing period.



**Fig 3b** (right) Circumferential infrabony defect immediately before decontamination.



**Fig 3c** CO<sub>2</sub> laser irradiation of the defect for sufficient decontamination.



**Fig 3d** Augmentation of the defect with autogenous bone.



**Fig 3e** Coverage of the augmented area with a collagen membrane (Biogide) and fixation with titanium pins.



**Fig 3f** (left) Complete bone fill 2 months after surgery.

**Fig 3g** (right) Bone fill after 2 years of loading (observe the resorption of the autogenous bone grafting material at the top of the machined-surfaced implant).



**Table 2** Clinical indices before and after laser irradiation and augmentation

	Preoperative	Postoperative	P
PI	1.01 ± 1.37	0.98 ± 1.20	NS
SBI	2.76 ± 0.35	1.03 ± 0.85	< .01
PD (mm)	6.00 ± 2.03	2.48 ± 0.63 mm	< .01
KM (mm)	2.30 ± 1.45	2.41 ± 1.39 mm	NS

PI = Plaque Index; SBI = Sulcus Bleeding Index; PD = probing depth; KM = width of keratinized mucosa; NS = no significance.

**Table 3** Vertical bone loss in the peri-implant bony defects\*

Bone loss	No. of defects	
	Preoperative	Postoperative
0–2 mm	0	13
1/3 of implant length	8	6
2/3 of implant length	7	0
To the apical area	4	0

\*Follow up: 27.10 ± 17.83 months.

**Table 4** Studies on the treatment of peri-implantitis

Study	Type	No. of implants	Decontamination	Bone fill	Reosseointegration
Grunder et al (1993)	Animal (dog)	20 (Screw-vent)	Air flow + membrane	—	—
Jovanovic et al (1993)	Animal (dog)	30 (Brånemark, IMZ, Integral)	Air flow + citric acid	+	Not stated
Ericsson et al (1996)	Animal (dog)	30 (Brånemark)	Amoxicillin + metronidazole (systemic) for 3 wk	—	—
Wetzel et al (1999)	Animal (dog)	41 machined and TPS or SLA (ITI)	Systemic antibiotic (Metronidazole) + cleaning + CHX	60%–80%	0.1 mm (smooth)/0.6 mm (rough)
Bach et al (2000)	Clinical	Not stated (20 patients)	Cleaning, CHX, 810 nm Diode laser	11%/30% recurrence (test/control)	Not stated
Behneke et al (2000)	Clinical	25 (ITI)	Air flow + bone graft + systemic Antibiotics	86% in 3 mo 100% in 3 years	Not stated
Haas et al (2000)	Clinical	24 (IMZ)	Systemic antibiotics, soft laser + membrane + bone graft	+	—
Deppe et al (2001)	Animal (dog)	35 (PVS) 32 (LAS) 34 (LAS + PVS)	CO <sub>2</sub> -laser vs PVS and LAS + PVS	PVS: + LAS: +++ PVS+LAS: ++	Not stated
Persson et al (2001)	Animal (dog)	24 ITI (Turned/SLA)	Systemic antibiotics + irrigation with NaCl	Turned: 72% SLA: 76%	Turned: 22% SLA: 84%

with only autogenous bone graft, at least two thirds of the bony defect was filled with bone because of some bone graft resorption over time.

## Discussion

Nonsurgical methods to treat peri-implantitis include mechanical instrumentation and use of a variety of antibacterial agents. The use of curettes or ultrasonic instruments in

the treatment of peri-implantitis has been criticized because such tools may damage the implant surface.<sup>21–23</sup> Alternative treatment protocols with antibiotics for the treatment of peri-implantitis do not lead to sufficient bone fill or reosseointegration (Table 4).

Animal studies,<sup>5,10,13,24–27</sup> clinical case reports,<sup>6,28</sup> and two clinical studies with larger groups of patients<sup>29,30</sup> have addressed the surgical treatment of peri-implant bony defects. However, no treatment method attained excellent results. Other studies recommended apically positioning the flaps for better plaque control and polishing the threads of implants, especially when wide bony defects are present.<sup>11,31,32</sup> However, such treatment methods are associated with cosmetic problems in the esthetic zone. Citric acid and sandblasting,<sup>11,25</sup> sandblasting alone,<sup>24,30,33</sup> or chlorhexidine irrigations<sup>27</sup> have also been recommended. These methods seem to be as effective as using curettes or ultrasonic instruments for the treatment of peri-implant lesions, although implant decontamination using sandblasting units may be associated with risks such as emphysema.<sup>34</sup>

In a clinical study by Khoury and Buchmann,<sup>35</sup> no differences were found when citric acid and systemic antibiotic therapy were used for implant decontamination prior to bone grafting with or without membrane coverage. Persson et al<sup>36</sup> treated peri-implant bony defects in animals with local irrigation of sodium chloride (NaCl) solution in combination with systemic administration of amoxicillin and metronidazole. Turned (polished) surfaced implants showed 22% reosseointegration, while sand-blasted, large grit, acid-etched implants demonstrated 84% reosseointegration.

The present series of clinical cases with deep peri-implant infrabony defects showed extensive bone fill 27 months after laser decontamination

and bone augmentation. Using the described protocol, the authors were able to decontaminate the implant surface efficiently and augment infrabony defects with either autogenous bone or bone grafting materials. The good coagulation properties of the laser allow for excellent stabilization of the clot in combination with the graft in close contact with the implant surface, which is necessary to promote reosseointegration. The defects treated had a mean depth of approximately 7 mm. Treatment was accomplished without inducing recession. Furthermore, both osseous fill and reosseointegration were achieved. This conclusion is supported by the histologic observations by Deppe et al<sup>20</sup> and Stübinger et al,<sup>37</sup> who note that reosseointegration occurred when bone fill was induced around peri-implant defects.

The ability of lasers to reduce the bacterial challenge around implants has been previously documented. Several studies demonstrated a significant reduction of periodontopathogens *in vitro* after use of CO<sub>2</sub> lasers.<sup>38,39</sup> A 810-nm diode laser,<sup>40,41</sup> an erbium-doped yttrium aluminum garnet (Er:YAG) laser,<sup>42</sup> and a 905-nm soft laser combined with photodynamic therapy<sup>43</sup> also decreased bacterial levels after laser therapy. The physical properties of laser light and its interactions with the tissues—such as reflection, scattering, transmission, and absorption—explain why the implant surface may be decontaminated in all areas as well as within the threads. The light, along with its antibacterial effects, may be absorbed by the implant and adjacent surrounding tissues or may be reflected by the metal



surface, causing a slight rise of tissue temperature.

The CO<sub>2</sub> laser does not damage the implant surface<sup>38,44</sup> during irradiation compared to other laser systems, such as the neodymium (Nd):YAG,<sup>44</sup> Er:YAG,<sup>45</sup> or diode 810-nm (unpublished data) if the correct power and frequency are used. The CO<sub>2</sub> laser (continuous or pulsed mode) does not modify the implant surface in the power range of 2.0 to 6.0 watts. Melting or loss of porosity was not found in titanium implants.<sup>44</sup> Currently, the only alternative to the CO<sub>2</sub> laser seems to be a diode laser with 980-nm wavelength, which also does not cause dramatic changes during laser irradiation.<sup>46</sup> Data regarding other laser systems are lacking.

It has also been noted that irradiation of the implant does not significantly increase the temperature of the implant body<sup>47-50</sup>; therefore, osteoblastic activity and soft tissue attachment may not be compromised.<sup>51</sup> Kato et al<sup>38</sup> noted a slight temperature increase, which did not negatively influence attachment of fibroblasts or osteoblastic cells on the implant surface. With regard to the impact of the laser on the surrounding tissue of the implant, there is decreased penetration depth due to absorption of the CO<sub>2</sub> radiation by the high water content of the mucosa.

Several authors indicated that low-intensity lasers<sup>43,52,53</sup> and high-intensity lasers<sup>20,42,54,55</sup> are useful for treating peri-implant defects. The application of toluidine blue and irradiation with a diode soft laser and a wavelength of 905 nm for 1 minute caused a significant reduction of the periodonto-

pathogens in the peri-implant bony defects.<sup>43</sup> However, there are no histomorphometric data showing new bone formation and osseointegration after the use of this laser wavelength.

## Conclusion

This case series confirms that the use of a CO<sub>2</sub> laser in the treatment of peri-implantitis deserves consideration as an efficacious treatment modality. There appears to be little risk to the patient; however, special training of the surgeon is necessary regarding safety procedures and laser-tissue interactions. In addition, the costs of the laser unit and the wavelength must be considered. Along with decontamination of implant surfaces, the CO<sub>2</sub> laser has been used for soft tissue surgery,<sup>56</sup> surgery in the periodontal tissues,<sup>40</sup> or endodontic treatment,<sup>57</sup> and thus has various clinical applications in a private clinic.

## References

1. Albrektsson T, Dahl E, Enbom L, et al. Osseointegrated oral implants: A Swedish multicenter study of 8,139 consecutively inserted Noblepharma implants. *J Periodontol* 1988;59:287–296.
2. Berglundh T, Persson L, Klinge B. A systematic review of the incidence of biological and technical complications in implant dentistry reported in prospective longitudinal studies of at least 5 years. *J Clin Periodontol* 2002;29:197–212.
3. Esposito M, Worthington HV, Coulthard P, Thomsen P. Maintaining and re-establishing health around osseointegrated oral implants: A Cochrane systematic review comparing the efficacy of various treatments. *Periodontol* 2000 2003;33:204–212.
4. Lehmann B, Brägger U, Hämmerle CH, Fourmousis I, Lang NP. Treatment of an early implant failure according to the principles of guided tissue regeneration (GTR). *Clin Oral Implants Res* 1992;3:42–48.
5. Grunder U, Hürzeler MB, Schüpbach P, Strub JR. Treatment of ligature-induced periimplantitis using guided tissue regeneration: A clinical and histologic study in the beagle dog. *Int J Oral Maxillofac Implants* 1993;8:282–293.
6. Hämmerle CHF, Fourmousis I, Winkler JR, Weigle C, Brägger U, Lang NP. Successful bone fill in late periimplant defects using guided bone regeneration. A short communication. *J Periodontol* 1995;66:303–308.
7. Esposito M, Hirsch J, Lekholm U, Thomsen P. Differential diagnosis and treatment strategies for biologic complications and failing oral implants: A review of the literature. *Int J Oral Maxillofac Implants* 1999;14:473–490.
8. Klinge B, Gustafsson A, Berglundh T. A systematic review of the effect of anti-infective therapy in the treatment of periimplantitis. *J Clin Periodontol* 2002;29 (suppl 3):213–225.
9. Parham PL, Cobb CM, French A. Effect of an air-powder abrasive system on plasma-sprayed titanium implant surface: An in vitro evaluation. *J Oral Implantol* 1989;15:78–86.
10. Schüpbach P, Hürzeler MB, Grunder U. Implant-tissue interfaces following treatment of periimplantitis using guided tissue regeneration: A light and electron microscopic study. *Clin Oral Implants Res* 1994;5:55–65.
11. Jovanovic SA. The management of periimplant breakdown around functioning osseointegrated dental implants. *J Periodontol* 1993;64:1176–1183.
12. Lang NP, Mombelli A, Tonnetti MS, Brägger U, Hämmerle CHF. Clinical trials on therapies for periimplant infections. *Ann Periodontol* 1997;2:343–356.
13. Jovanovic SA, Kenney B, Carranza FA, Donath K. The regenerative potential of claque-induced periimplant bone defects treated by a submerged membrane technique: An experimental study. *Int J Oral Maxillofac Surg* 1992;7:233–245.
14. Zablitzky MH. Chemotherapeutics in implant dentistry. *Implant Dent* 1993;2:19–25.
15. Mombelli A, Lang NP. Antimicrobial treatment of periimplant infections. *Clin Oral Implants Res* 1992;3:162–168.
16. Mombelli A. Etiology, diagnosis, and treatment considerations in periimplantitis. *Curr Opin Periodontol* 1997;4:127–136.
17. Schenk G, Flemming TF, Betz T, Reuther J, Klaiber B. Controlled local delivery of tetracycline HCl in the treatment of periimplant mucosal hyperplasia and mucositis. A controlled case series. *Clin Oral Implants Res* 1997;8:427–433.
18. Sbordone L, Barone A, Ramaglia L, Ciaglia RN, Iacono VJ. Antimicrobial susceptibility of periodontopathic bacteria associated with failing implants. *J Periodontol* 1995;66:69–74.
19. Roos-Janssaker AM, Renvert S, Egelberg J. Treatment of periimplant infections: A literature review. *J Clin Periodontol* 2003;30:467–485.
20. Deppe H, Horch HH, Henke J, Donath K. Peri-implant care of ailing implants with the carbon dioxide laser. *Int J Oral Maxillofac Implants* 2001;16:659–667.

21. Thomson-Neal D, Evans GH, Meffert RM. Effects of various prophylactic treatments on titanium, sapphire, and hydroxyapatite-coated implants: A SEM study. *Int J Periodontics Restorative Dent* 1989;9:301–311.
22. Fox SC, Moriarty JD, Kusy RP. The effects of scaling a titanium implant surface with metal and plastic instruments: An in vitro study. *J Periodontol* 1990;61:485–490.
23. Rapley JW, Swan RH, Hallmon WW, Mills MP. The surface characteristics produced by various oral hygiene instruments and materials on titanium implant abutments. *Int J Oral Maxillofac Implants* 1990;5:47–52.
24. Hürzeler MB, Quinones CR, Morrison EC, Caffesse RG. Treatment of periimplantitis using guided bone regeneration and bone grafts, alone or in combination, in beagle dogs. Part I: Clinical findings and histologic observations. *Int J Oral Maxillofac Implants* 1995;10:474–484.
25. Hanisch O, Tatakis DN, Boskovic MM, Rohrer MD, Wikesjö UM. Bone formation and reosseointegration in periimplantitis defects following surgical implantation of rhBMP-2. *Int J Oral Maxillofac Implants* 1997;12:604–610.
26. Hürzeler MB, Quinones CR, Schüpbach P, Morrison EC, Caffesse RG. Treatment of periimplantitis using guided bone regeneration and bone grafts, alone or in combination, in beagle dogs. Part 2: Histologic findings. *Int J Oral Maxillofac* 1997;12:168–175.
27. Wetzel AC, Vlassis J, Caffessee RG, Hämmerle CH, Lang NP. Attempts to obtain reosseointegration following experimental periimplantitis in dogs. *Clin Oral Implants Res* 1999;10:111–119.
28. Bretz WA, Matuck AN, de Oliveira G, Moretti AJ, Bretz WA. Treatment of retrograde periimplantitis: Clinical report. *Implant Dent* 1997;6:287–290.
29. Augthun M, Richter EJ, Hauptmann S, Yildirim M. Untersuchung und Behandlung von tiefen periimplantären Knochentaschen mit e-PTFE-Membranen. *Z Zahnärztl Implantol* 1992;8:246–250.
30. Behneke A, Behneke N, dHoedt B. Treatment of peri-implantitis defects with autogenous bone grafts: Six month to 3-year results of a prospective study in 17 patients. *Int J Oral Maxillofac Implants* 2000;15:125–138.
31. Kwan JY, Zablotzky MH. The ailing implant. *J Calif Dent Assoc* 1991;12:51–56.
32. Flemmig TF. Infektionen bei osseointegrierten Implantaten—Hintergründe und klinische Indikationen. *Implantologie* 1994;1:9–21.
33. Singh G, O'Neal RB, Brenman WA, Strong SL, Horner JA, Van Dyke TE. Surgical treatment of induced periimplantitis in the micro pig: Clinical and histological analysis. *J Periodontol* 1993;64:984–989.
34. van de Velde E, Thielems P, Schautteet H, Vanclooster R. Subcutaneous emphysema of the oral floor during cleaning of a bridge fixed on a IMZ implant. Case report. *Rev Belge Med Dent* 1991;46:64–71.
35. Khoury F, Buchmann R. Surgical therapy of periimplant disease: A 3-year follow up study of cases treated with 3 different techniques of bone regeneration. *J Periodontol* 2001;72:1498–1508.
36. Persson LG, Berglundh T, Lindhe J, Sennerby L. Reosseointegration after treatment of peri-implantitis at different implant surfaces. An experimental study in the dog. *Clin Oral Implants Res* 2001;12:595–603.
37. Stübinger S, Henke J, Donath K, Deppe H. Bone regeneration after periimplant care with the CO<sub>2</sub> laser: A fluorescence microscopic study. *Int J Oral Maxillofac Implants* 2005;20:203–210.
38. Kato T, Kusakari H, Hoshino E. Bactericidal efficacy of carbon dioxide laser against bacteria-contaminated titanium implant and subsequent cellular adhesion to irradiated area. *Lasers Surg Med* 1998;23:299–306.
39. Romanos GE, Purucker P, Bernimoulin JP, Nentwig GH. Bactericidal efficacy of CO<sub>2</sub>-laser against bacteria-contaminated sandblasted titanium implants. *J Oral Laser Applications* 2002;2:171–174.

40. Moritz A, Schoop U, Goharkhay K, et al. Treatment of periodontal pockets with a diode laser. *Lasers Surg Med* 1998;22:302–311.
41. Kreisler M, Kohnen W, Marinello C, et al. Antimicrobial efficacy of semiconductor laser irradiation on implant surfaces. *Int J Oral Maxillofac Implants* 2003;18:706–711.
42. Schwarz F, Sculean A, Romanos G, et al. Influence of different treatment approaches on the removal of plaque biofilms and the viability of SaOs-2 osteoblasts grown on titanium implants. *Clin Oral Investig* 2005;20:1432–6981.
43. Haas R, Dörtbudak O, Mensdorff-Pouilly N, Mailath G. Elimination of bacteria on different implant surfaces through photosensitization and soft laser. An in vitro study. *Clin Oral Implants Res* 1997;8:249–254.
44. Romanos GE, Everts H, Nentwig GH. Alterations of the implant surface after CO<sub>2</sub>- or Nd:YAG-laser irradiation. A SEM-examination. *J Oral Laser Applications* 2001;1:29–33.
45. Rechmann P, Sadegh HM, Goldin DS, Hennig T. Zur Oberflächenmorphologie von Implantaten nach Laserbestrahlung. *Dtsche Zahnärztl Z* 2000;55:371–376.
46. Romanos GE, Everts H, Nentwig GH. Effects of the diode (980 nm) and Nd:YAG (1064 nm) laser irradiation on titanium discs. A SEM examination. *J Periodontol* 2000;71:810–815.
47. Chu RT, Watanabe L, White JM, Marshall GW, Marshall SJ, Hutton JE. Temperature rise and surface modification of lased titanium cylinders [abstract]. *J Dent Res* 1992;71:144.
48. Ganz CH. Evaluation of the safety of the carbon dioxide laser used in conjunction with root form implants: A pilot study. *J Prosthet Dent* 1994;71:27–30.
49. Oyster DK, Parker WB, Gher ME. CO<sub>2</sub> lasers and temperature changes of titanium implants. *J Periodontol* 1995;66:1017–1024.
50. Mouhyi J, Sennerby L, Nammour S, Gillaume P, Van Reck J. Temperature increases during surface decontamination of titanium implants using CO<sub>2</sub> laser. *Clin Oral Implants Res* 1999;10:54–61.
51. Romanos GE, Crespi R, Barone A, Covani U. Osteoblast attachment on titanium disks after laser irradiation. *Int J Oral Maxillofac Implants* 2006;21:232–236.
52. Haas R, Baron M, Dörtbudak O, Watzek G. Lethal photosensitization, autogenous bone, and e-PTFE membrane for the treatment of periimplantitis: Preliminary results. *Int J Oral Maxillofac Implants* 2000;15:374–382.
53. Dörtbudak O, Haas R, Bernhart T, Mailath-Pokorny G. Lethal photosensitization for decontamination of implant surfaces in the treatment of periimplantitis. *Clin Oral Implants Res* 2001;12:104–108.
54. Bach G, Neckel C, Mall C, Krekeler G. Conventional versus laser-assisted therapy of periimplantitis: A five-year comparative study. *Implant Dent* 2000;9:247–251.
55. Romanos GE. Treatment of peri-implant lesions using different laser systems. *J Oral Laser Applications* 2002;2:75–81.
56. Catone GA. Lasers in periodontal surgery. In: Catone GA, Aling CC (eds). *Laser Application in Oral and Maxillofacial Surgery*. Philadelphia: Saunders, 1997:181–196.
57. Moritz A, Gutknecht N, Schoop U, Goharkhay K, Doertbudak O, Sperr W. Irradiation of infected root canals with a diode laser in vivo: Results of microbiological examinations. *Lasers Surg Med* 1997;21:221–226.